Drugs / Vaxneuvance
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Vaxneuvance | — | 2021-12-13 | europa.eu ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy5 trials | ||||||
| Phase 3 | NCT06975878 Comparator | May 2025 → Aug 2027 expected | — | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06806137 Background | May 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06855160 Background | Apr 2025 → Sep 2026 overdue | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06740630 Background | Jan 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06693895 Background | Nov 2024 → Nov 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vaxneuvance | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06740630 ↗ |
| Modality | Vaccine | “15-valent pneumococcal conjugate (Vaxneuvance) vaccine” NCT06693895 ↗ |
| Route | Intramuscular | “co-administered intramuscularly” NCT06693895 ↗ |